CY1116561T1 - ANTI-ALPHA2 INTEGRINE ANTIBODIES AND THEIR USES - Google Patents

ANTI-ALPHA2 INTEGRINE ANTIBODIES AND THEIR USES

Info

Publication number
CY1116561T1
CY1116561T1 CY20151100571T CY151100571T CY1116561T1 CY 1116561 T1 CY1116561 T1 CY 1116561T1 CY 20151100571 T CY20151100571 T CY 20151100571T CY 151100571 T CY151100571 T CY 151100571T CY 1116561 T1 CY1116561 T1 CY 1116561T1
Authority
CY
Cyprus
Prior art keywords
antibodies
integrin
integrine
alpha2
bind
Prior art date
Application number
CY20151100571T
Other languages
Greek (el)
Inventor
Elias Lazarides
Catherine Woods
Mark A Bernard
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06804739.8A external-priority patent/EP1948798B1/en
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Publication of CY1116561T1 publication Critical patent/CY1116561T1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση αναφέρεται σε αντισώματα αντι-α2 ιντεγκρίνης και στις χρήσεις τους. Περιγράφονται εξανθρωπισμένα αντισώματα, τα οποία προσδένονται στην I περιοχή της α2 ιντεγκρίνης και αναστέλλουν την αλληλεπίδραση της α2β1 ιντεγκρίνης με το κολλαγόνο. Περιγράφονται επίσης οι θεραπευτικές χρήσεις των αντισωμάτων αντι-α2 ιντεγκρίνης στην αντιμετώπιση των διαμεσολαβούμενων από την α2β1 διαταραχών, συμπεριλαμβανομένων των αντισωμάτων αντι-α2 ιντεγκρίνης που προσδένονται στην α2 ιντεγκρίνη χωρίς να ενεργοποιούνται τα αιμοπετάλια.The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are described, which bind to the α region of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also described are therapeutic uses of anti-α2 integrin antibodies in the treatment of α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.

CY20151100571T 2005-11-18 2015-07-01 ANTI-ALPHA2 INTEGRINE ANTIBODIES AND THEIR USES CY1116561T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73830305A 2005-11-18 2005-11-18
EP06804739.8A EP1948798B1 (en) 2005-11-18 2006-11-17 Anti-alpha2 integrin antibodies and their uses

Publications (1)

Publication Number Publication Date
CY1116561T1 true CY1116561T1 (en) 2017-03-15

Family

ID=58459770

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100571T CY1116561T1 (en) 2005-11-18 2015-07-01 ANTI-ALPHA2 INTEGRINE ANTIBODIES AND THEIR USES

Country Status (1)

Country Link
CY (1) CY1116561T1 (en)

Similar Documents

Publication Publication Date Title
CY1119454T1 (en) ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
CY1121162T1 (en) M-CSF-SPECIAL MONOCLONIC ANTIBODY AND ITS USE
EA016245B9 (en) Anti-alpha2 integrin antibodies and their uses
CY1119890T1 (en) TREATMENT TREATMENT OF TREATMENT USING SPECIAL ANTI-ANTI-L1
CY1116913T1 (en) MODIFIED FAB Fragrances
CY1121672T1 (en) ANTIBODIES THAT BIND IL-17A AND IL-17F
NL301089I2 (en) imlifidase
CY1125025T1 (en) 2-FORMYL-3-HYDROXYPHENYLOXIMETHYL COMPOUNDS CAPABLE OF ADJUSTING HEMOSPHERIN
CY1112739T1 (en) ANTI-CD79B ANTIBODIES AND IMMUNIZATIONS AND METHODS OF USE
CY1108767T1 (en) AREAS OF SYNTHETIC TREATMENT WITH MODIFIED BATHING PROPERTIES IN THE MORAL AREAS DIFFERENT AREAS
CY1116632T1 (en) ANTIBODIES DETERMINATORS OF THE HUMAN RECOVERY STAGES
CY1122476T1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFRI)
DK1951759T3 (en) Anti-EGFR antibodies
CY1119412T1 (en) METHODS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC FACTOR
CY1115871T1 (en) METHODS FOR TREATMENT OF URINARY ARTHRITIS
CY1113640T1 (en) METHODS FOR TREATMENT OF Rheumatoid Arthritis
CY1110571T1 (en) OPTIONAL MEDICAL VASCULAR OPTIONS-2
CY1111194T1 (en) OPTIONALLY ACCESSIBLE PEPPININYLI UNIVERSES
CY1112912T1 (en) MODIFIED ANTIBODIES ANTI-IL-23P19
ATE455127T1 (en) HUMAN ANTI-HUMAN CD3 BINDING MOLECULES
CY1124153T1 (en) ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127
CY1120424T1 (en) HUMAN BATTERIES PROTECTED BY POLYNECTORS, POLYNUCLEOTICES CODING WITH THESE Peptides And Their
CY1118710T1 (en) COMPOSITIONS FOR TREATMENT OF MULTIPLE SCIENCE
CY1118918T1 (en) B cell extinction agents, such as ENANTI-CD20 antibodies or their fragments for the treatment of chronic fatigue syndrome
DE60321041D1 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS